Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 1/20 | 0.54 |
| ▸ | PPARA | Q07869 | 1/20 | 0.54 |
| ▸ | ATM | Q13315 | 1/20 | 0.48 |
| ▸ | MME | P08473 | 4/20 | 0.47 |
| ▸ | MMEL1 | Q495T6 | 2/20 | 0.47 |
| ▸ | ACE | P12821 | 3/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | APP | P05067 | 3/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20586743 | 1.00 | PPARG (0.54) | PPARGPPARAATMMMEMMEL1 | |
| SCHEMBL17157150 | 1.00 | PPARG (0.54) | PPARGPPARAATMMMEMMEL1 | |
| SCHEMBL17165123 | 0.90 | PPARG (0.48) | PPARGPPARAATMMEN1KMT2A | |
| SCHEMBL12880113 | 0.90 | PPARG (0.48) | PPARGPPARAATMMEN1KMT2A | |
| SCHEMBL17165122 | 0.90 | PPARG (0.48) | PPARGPPARAATMMEN1KMT2A | |
| SCHEMBL30454910 | 0.86 | PPARG (0.55) | PPARGPPARAATMMEN1KMT2A | |
| SCHEMBL2789835 | 0.85 | PPARG (0.54) | PPARGPPARAATMMMEMEN1 | |
| SCHEMBL2789840 | 0.85 | PPARG (0.54) | PPARGPPARAATMMMEMEN1 | |
| SCHEMBL2617240 | 0.85 | PPARG (0.54) | PPARGPPARAATMMMEMEN1 | |
| SCHEMBL15150564 | 0.85 | ATM (0.53) | PPARGPPARAATMMMEMMEL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10159745-B2 | Tubulysin derivatives | MEDIMMUNE, LLC (US) | 2018-12-25 | — | — | US | disclosed |
| US-9580467-B2 | Antiproliferative compounds, conjugates thereof, methods therefor, and uses thereof | E. R. SQUIBB & SONS, L.L.C. (US) | 2017-02-28 | — | — | US | disclosed |
| EP-3129362-A1 | TUBULYSIN DERIVATIVES | Medimmune, LLC (US) | 2017-02-15 | — | — | EP | disclosed |
| US-20160339114-A1 | TUBULYSIN DERIVATIVES | MEDIMMUNE LLC (US) | 2016-11-24 | — | — | US | disclosed |
| US-9427479-B2 | Tubulysin derivatives | MEDIMMUNE LLC (US) | 2016-08-30 | — | — | US | disclosed |
| US-20160060294-A1 | ANTIPROLIFERATIVE COMPOUNDS, CONJUGATES THEREOF, METHODS THEREFOR, AND USES THEREOF | E. R. SQUIBB & SONS, L.L.C. | 2016-03-03 | — | — | US | disclosed |
| US-9226974-B2 | Antiproliferative compounds, conjugates thereof, methods therefor, and uses thereof | E. R. SQUIBB & SONS, L.L.C. (US) | 2016-01-05 | — | — | US | disclosed |
| US-20150291657-A1 | TUBULYSIN DERIVATIVES | MEDIMMUNE LLC (US) | 2015-10-15 | — | — | US | disclosed |
| WO-2015157594-A1 | TUBULYSIN DERIVATIVES | MEDIMMUNE LLC (US) | 2015-10-15 | — | — | WO | disclosed |
| US-20140323690-A1 | ANTIPROLIFERATIVE COMPOUNDS, CONJUGATES THEREOF, METHODS THEREFOR, AND USES THEREOF | E. R. SQUIBB & SONS, L.L.C. | 2014-10-30 | — | — | US | disclosed |
| US-8802632-B2 | Antiproliferative compounds, conjugates thereof, methods therefor, and uses thereof | MEDAREX, L.L.C. (US) | 2014-08-12 | — | — | US | disclosed |
| US-8772542-B2 | Antiproliferative compounds, conjugates thereof, methods therefor, and uses thereof | MEDAREX, L.L.C. (US) | 2014-07-08 | — | — | US | disclosed |
| US-8772543-B2 | Antiproliferative compounds, conjugates thereof, methods therefor, and uses thereof | MEDAREX, L.L.C. (US) | 2014-07-08 | — | — | US | disclosed |
| US-20130204033-A1 | ANTIPROLIFERATIVE COMPOUNDS, CONJUGATES THEREOF, METHODS THEREFOR, AND USES THEREOF | MEDAREX, INC. (US) | 2013-08-08 | — | — | US | disclosed |
| US-20130189256-A1 | ANTIPROLIFERATIVE COMPOUNDS, CONJUGATES THEREOF, METHODS THEREFOR, AND USES THEREOF | MEDAREX, INC. (US) | 2013-07-25 | — | — | US | disclosed |
| US-20110027274-A1 | ANTIPROLIFERATIVE COMPOUNDS, CONJUGATES THEREOF, METHODS THEREFOR, AND USES THEREOF | MEDAREX, INC. (US) | 2011-02-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160060294-A1 | ANTIPROLIFERATIVE COMPOUNDS, CONJUGATES THEREOF, METHODS THEREFOR, AND USES THEREOF | WEE1, NGLY1, CD81 | PPARG 4389/4885PPARA 3538/4885ATM 4640/4885 |
| US-20110027274-A1 | ANTIPROLIFERATIVE COMPOUNDS, CONJUGATES THEREOF, METHODS THEREFOR, AND USES THEREOF | WEE1, NGLY1, CD81 | PPARG 4389/4885PPARA 3538/4885ATM 4640/4885 |
| US-20130189256-A1 | ANTIPROLIFERATIVE COMPOUNDS, CONJUGATES THEREOF, METHODS THEREFOR, AND USES THEREOF | WEE1, NGLY1, CD81 | PPARG 4389/4885PPARA 3538/4885ATM 4640/4885 |
| US-10159745-B2 | Tubulysin derivatives | TEKT1, TWF2, TEK | PPARG 4878/4885PPARA 4852/4885ATM 3553/4885 |
| US-20150291657-A1 | TUBULYSIN DERIVATIVES | TEKT1, TWF2, TEK | PPARG 4878/4885PPARA 4852/4885ATM 3553/4885 |
| US-20140323690-A1 | ANTIPROLIFERATIVE COMPOUNDS, CONJUGATES THEREOF, METHODS THEREFOR, AND USES THEREOF | WEE1, NGLY1, CD81 | PPARG 4389/4885PPARA 3538/4885ATM 4640/4885 |
| US-20160339114-A1 | TUBULYSIN DERIVATIVES | TEKT1, TWF2, TEK | PPARG 4878/4885PPARA 4852/4885ATM 3553/4885 |
| US-20130204033-A1 | ANTIPROLIFERATIVE COMPOUNDS, CONJUGATES THEREOF, METHODS THEREFOR, AND USES THEREOF | WEE1, NGLY1, CD81 | PPARG 4389/4885PPARA 3538/4885ATM 4640/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.